Lunai Bioworks Identifies Three Revenue Streams: AI Drug Discovery, Bio-Defense, and Immunotherapy
Lunai Bioworks Inc. outlined three revenue-generating segments: AI drug discovery, bio-defense, and immunotherapy in a shareholder letter. The Sacramento-based company has completed its AI platform and is negotiating partnerships with pharmaceutical firms. Key collaborations include working with Supernus Pharmaceuticals on epilepsy and a new oncology project for colorectal cancer. The bio-defense segment includes Sentinel, Pathfinder, and CounterAct. Lunai's dendritic cell therapy showed promise in pancreatic tumor regression, with licensing discussions underway.
Theia Market Signal Identification - AI Assisted
Lunai Bioworks Inc. has identified three revenue-generating segments: AI drug discovery, AI bio-defense, and immunotherapy. The Sacramento company completed its AI platform in the past year and is negotiating partnerships with pharmaceutical companies.
In the AI drug discovery segment, Lunai collaborates with Supernus Pharmaceuticals for an epilepsy trial and has a new oncology partnership for colorectal cancer. The bio-defense segment includes Sentinel, Pathfinder, and CounterAct, with negotiations ongoing with governmental and private partners. For immunotherapy, Lunai's dendritic cell therapy showed complete regression of pancreatic tumors in preclinical models, with a letter of intent for licensing received.
Comments